Contrasting Oruka Therapeutics (ORKA) & Its Competitors

Oruka Therapeutics (NASDAQ:ORKAGet Free Report) is one of 39 public companies in the “Diagnostic substances” industry, but how does it compare to its rivals? We will compare Oruka Therapeutics to related businesses based on the strength of its risk, dividends, analyst recommendations, profitability, institutional ownership, valuation and earnings.

Volatility & Risk

Oruka Therapeutics has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500. Comparatively, Oruka Therapeutics’ rivals have a beta of 1.30, suggesting that their average stock price is 30% more volatile than the S&P 500.

Profitability

This table compares Oruka Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Oruka Therapeutics N/A -20.18% -19.51%
Oruka Therapeutics Competitors -1,868.98% -41.48% -26.23%

Valuation and Earnings

This table compares Oruka Therapeutics and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Oruka Therapeutics N/A -$5.34 million -4.45
Oruka Therapeutics Competitors $551.25 million $6.13 million -107.43

Oruka Therapeutics’ rivals have higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

56.4% of Oruka Therapeutics shares are owned by institutional investors. Comparatively, 44.7% of shares of all “Diagnostic substances” companies are owned by institutional investors. 22.7% of Oruka Therapeutics shares are owned by company insiders. Comparatively, 12.6% of shares of all “Diagnostic substances” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations for Oruka Therapeutics and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oruka Therapeutics 0 0 6 2 3.25
Oruka Therapeutics Competitors 871 816 1357 23 2.17

Oruka Therapeutics currently has a consensus target price of $43.17, suggesting a potential upside of 61.79%. As a group, “Diagnostic substances” companies have a potential upside of 41.98%. Given Oruka Therapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Oruka Therapeutics is more favorable than its rivals.

Summary

Oruka Therapeutics beats its rivals on 10 of the 13 factors compared.

Oruka Therapeutics Company Profile

(Get Free Report)

ARCA biopharma, Inc., a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products. The Company’s business focus combines expertise in cardiovascular pathophysiology, molecular genetics, clinical development and product commercialization. It is currently developing Gencaro (bucindolol hydrochloride), a cardiovascular drug for the treatment of chronic heart failure. The company is based in Broomfield, Colorado.

Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.